Free tool
FAERS Monitor: Qlosi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217836 or its brand name (Qlosi, Pilocarpine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,260
Serious
645
51% of reports
Hospitalization
274
Death reported
34
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective143
- headache104
- fatigue97
- pain96
- eye pain91
- dyspnoea85
- nausea80
- dizziness76
- diarrhoea74
- off label use70
- cough68
- fall67
- arthralgia62
- product dose omission issue57
- weight increased56
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 20 |
| 2006 | 6 |
| 2007 | 5 |
| 2008 | 15 |
| 2009 | 35 |
| 2010 | 43 |
| 2011 | 8 |
| 2012 | 14 |
| 2013 | 18 |
| 2014 | 15 |
| 2015 | 16 |
| 2016 | 7 |
| 2017 | 29 |
| 2018 | 40 |
| 2019 | 77 |
| 2020 | 93 |
| 2021 | 68 |
| 2022 | 119 |
| 2023 | 107 |
| 2024 | 140 |
| 2025 | 216 |
| 2026 | 152 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,899 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye painSignal | 91 | 27.0 | 22.1 | 2,252 |
| weight increasedSignal | 56 | 4.2 | 3.2 | 133 |
| coughSignal | 68 | 4.0 | 3.2 | 155 |
| fallSignal | 67 | 3.4 | 2.7 | 110 |
| product dose omission issueSignal | 57 | 3.2 | 2.5 | 87 |
| headacheSignal | 104 | 2.8 | 2.3 | 119 |
| painSignal | 96 | 2.6 | 2.2 | 96 |
| dizzinessSignal | 76 | 2.5 | 2.0 | 71 |
| dyspnoeaSignal | 85 | 2.5 | 2.0 | 78 |
| arthralgiaSignal | 62 | 2.5 | 2.0 | 55 |
| fatigueSignal | 97 | 2.1 | 1.7 | 55 |
| diarrhoea | 74 | 1.9 | 1.5 | 32 |
| drug ineffective | 143 | 1.8 | 1.6 | 55 |
| nausea | 80 | 1.7 | 1.4 | 23 |
| off label use | 70 | 1.3 | 1.1 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.